Affivant is a Basel, Switzerland based biotech company developing innate immune cell engagers for the treatment of solid tumors. We are currently raising Series A financing to take our lead asset into clinical development. AFVT-2101 is a CD16A x Folate Receptor alpha (FRα) bi-specific innate cell engager (ICE) with promising in vitro and in vivo efficacy and safety data. The ultra-high affinity, selective, CD16A engagement of AFVT-2101 overcomes limitations of Fc active, or Fc enhanced antibodies. AFVT-2101 is positioned to potentially treat a broad range of tumor types with low to high expression of FRα, differentiating from FRα targeting ADCs both in efficacy and safety. Clinical material is ready and IND submission package is complete. Key US sites are engaged. We are partnering with Evotec to develop a synergistic pipeline including a fully owned, iPSC-derived, modified, universal NK cell therapy.
.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Basel Stadt
Company HQ Country:
Switzerland
Year Founded:
2020
Main Therapeutic Focus:
Oncology
Lead Product in Development:
AFVT-2101 (FRa x CD16A bispecific)
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
